Elizabeth Evans, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1396273330
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,184 of the $3,297 with a category attached, or 66.2%. Intuitive Surgical accounts for 63.8% of it on its own, with 13 other manufacturers making up the rest.
Across 41 payments — averaging $80.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AstraZeneca$320
- GSK$200
- Merck$162
- AbbVie$145
- Caris MPI, Inc.$120
- plus $244 from 8 others
What the payments were for
- Food & beverage$1,11334%
- Education$2,18466%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $2,105 |
| AstraZeneca | 4 | $320 |
| GSK | 9 | $200 |
| Merck | 6 | $162 |
| AbbVie | 4 | $145 |
| Caris MPI, Inc. | 2 | $120 |
| Genmab U.S., Inc. | 2 | $52 |
| Integra Lifesciences Corporation | 1 | $41 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Eisai Inc. | 1 | $31 |
| Tempus AI, Inc | 1 | $29 |
| Boston Scientific | 1 | $20 |
| Atricure, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$2,000
- LYNPARZA$115
How this compares
$3,297 in reported general payments places this provider in the 55th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 41 | $306 |
| Ondansetron OdtOndansetron | 13 | $55 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
- Aleia CrimOklahoma City$862
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.